Last $0.70 USD
Change Today -0.0098 / -1.38%
Volume 7.5K
DSKX On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 1:39 PM 01/28/15 All times are local (Market data is delayed by at least 15 minutes).

ds healthcare group inc (DSKX) Snapshot

Open
$0.71
Previous Close
$0.71
Day High
$0.71
Day Low
$0.70
52 Week High
01/28/14 - $2.50
52 Week Low
12/22/14 - $0.56
Market Cap
11.4M
Average Volume 10 Days
33.9K
EPS TTM
$-0.16
Shares Outstanding
16.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DS HEALTHCARE GROUP INC (DSKX)

Related News

No related news articles were found.

ds healthcare group inc (DSKX) Related Businessweek News

No Related Businessweek News Found

ds healthcare group inc (DSKX) Details

DS Healthcare Group, Inc., doing business as DS Laboratories, develops and markets hair care, skin care, and personal care products in North America and internationally. Its hair care products include Revita and Revita LT shampoos, and Revita.Cor conditioner for hair growth stimulation; Dandrene, an antifungal shampoo to treat itchy scalp and dandruff; and Spectral line of products comprising Spectral.DNC spray formula, Spectral.DNC-L lotion, and Spectral DNC-N to re-grow hair through various pathways, as well as Spectral.RS, a topical treatment for men and women with advanced androgenic alopecia. The company’s skin care products comprise Hydroviton, a skin cleanser for oily and acne prone skin; Keramene, which is used to suppress hair growth and soften remaining hair strands; Oligo.DX, a cream to enhance the appearance of cellulite from women’s thighs, hips, and buttocks; and Trioxil, an acne cream. Its personal care products consist of Nirena, an intimate feminine care cleanser; and Revita.EPS, a product based on advanced bio-peptides that are designed to grow and enhance the length and girth of eyelash hair. DS Healthcare Group, Inc. markets and sells its products under the DS Laboratories, Polaris Labs, Sigma Skin, and Pure Guild brands through salons, spas, department stores, specialty retailers, and distributors. The company was formerly known as Divine Skin, Inc. and changed its name to DS Healthcare Group, Inc. in November 2012. DS Healthcare Group, Inc. is headquartered in Pompano Beach, Florida.

ds healthcare group inc (DSKX) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $169.9K
Compensation as of Fiscal Year 2013.

ds healthcare group inc (DSKX) Key Developments

DS Healthcare Group, Inc., Annual General Meeting, Jan 12, 2015

DS Healthcare Group, Inc., Annual General Meeting, Jan 12, 2015., at 14:00 US Eastern Standard Time. Location: 1601 Green Road. Agenda: To approve the election of four directors; to consider the ratification of the appointment of Marcum LLP as its independent registered public accounting firm; and to consider any other business as may properly come before the meeting.

DS Healthcare Group, Inc. Receives Non-Compliance Notice From NASDAQ

On December 16, 2014, DS Healthcare Group, Inc. received a letter from the listing qualifications department staff of the NASDAQ Stock Market (NASDAQ) notifying the company that for the last 30 consecutive business days the bid price of the company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of NASDAQ listing rule 5550(a)(2). In accordance with listing rule 5810(c)(3)(A), the company has 180 calendar days, or until June 15, 2015, to regain compliance with the minimum bid price rule. To regain compliance, the closing bid price of the company’s common stock must be at least $1.00 per share for a minimum of ten consecutive business days (or such longer period of time as the NASDAQ staff may require in some circumstances, but generally not more than 20 consecutive business days) before June 15, 2015. If the company’s common stock does not achieve compliance by June 15, 2015, the company may be eligible for an additional 180-day period to regain compliance if it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards, with the exception of the bid price requirement, and provides written notice to NASDAQ of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. However, if it appears to the NASDAQ staff that the company will not be able to cure the deficiency, or if the company does not meet the other listing standards, NASDAQ could provide notice that the company’s common stock will become subject to delisting. In the event the company receives notice that its common stock is being delisted, NASDAQ rules permit the company to appeal any delisting determination by the NASDAQ staff to a Hearings Panel. The company currently meets the continued listing requirement for market value of publicly held shares and all other initial listing standards of the NASDAQ Stock Market, with the exception of the bid price requirement. The company intends to actively monitor the closing bid price of its common stock between now and June 15, 2015 and will evaluate available options to resolve the deficiency and regain compliance with the minimum bid price rule.

DS Healthcare Group, Inc. Announces Financial Results for the Third Quarter and Nine Months Ended September 30, 2014

DS Healthcare Group, Inc. announced financial results for the third quarter and nine months ended September 30, 2014. For the quarter, net revenues were $3,278,117, an increase of 2.4% over revenues of $3,200,189 in the year-earlier period. Revenue growth in the third quarter was driven by higher sales from the company's Mexican subsidiary. This growth was partially offset by a reduction in domestic sales due to $1 million in open orders that are scheduled for delivery during the fourth quarter. Net loss narrowed by 94.8% to $54,496 or $0.00 per share from $1,053,406 or $0.08 in the same period of 2013. On an adjusted EBITDAS basis, a non-GAAP financial measure resulted in a gain of $94,018 compared to a loss of $777,865 in the year-earlier period. For the nine months, net revenues were $9,707,504, a 8.4% decline from revenues of $10,593,035 for the nine months ended September 30, 2013. Net revenue growth by the company's Mexican subsidiary was offset by a decrease in sell-through in foreign markets due to pending regulatory licensing and a decline in recorded domestic sales due to backorders that were pending completion and shipments. The company's net loss decreased by 32.4% to $1,533,617 or $0.10 per share in the first nine months of 2014 from $2,268,463 or $0.19 per share in the same period of 2013.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DSKX:US $0.70 USD -0.0098

DSKX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Johnson & Johnson $102.80 USD +0.71
Procter & Gamble Co/The $86.07 USD -0.42
View Industry Companies
 

Industry Analysis

DSKX

Industry Average

Valuation DSKX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.9x
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DS HEALTHCARE GROUP INC, please visit www.dslaboratories.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.